Compare Crispr Therapeutics AG (CRSP) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs TORM plc — how do they compare? Crispr Therapeutics AG trades at $50.36 (market cap $4.97B), while TORM plc trades at $29.02 (market cap $3.02B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and TORM plc pays a 9.52% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TRMD | |
|---|---|---|
Market Cap | $4.97B | $3.02B |
Sector | Health | Technology |
52-Week High | $76.78 | $34.87 |
52-Week Low | $44.34 | $17.46 |
Enterprise Value | $3.32B | $3.90B |
Dividend Yield | — | 9.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
TRMD trades at $28.86, down 2.1% today, with a bullish technical signal supported by moving averages despite neutral oscillators. The company shows strong fundamentals with a P/E of 8.62, net income margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, highlighting strong freight market conditions and operational execution.
Outlook remains positive with 100% analyst buy ratings and attractive valuation metrics. Key opportunities include the upcoming Q2 2026 earnings report and consistent dividend payments. Risks include earnings volatility, geopolitical impacts on shipping rates, and competitive pressures in the tanker market that could affect future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
